1-(2-羟基苯基)哌嗪二氢溴酸

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 中文名称: 1-(2-羟基苯基)哌嗪二氢溴酸
• 英文名称: hydron;2-piperazin-1-ylphenol;dibromide
• 化学式: C10H16Br2N2O
• mdl: MFCD00040814
• 分子量: 340.05
• InChiKey: YWZWSACJABVWJL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.0
• 重原子数：
  15
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  41.3
• 氢给体数：
  3
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  三乙胺 、 1-(2-羟基苯基)哌嗪二氢溴酸 、 二碳酸二叔丁酯 在 ice 、 水 作用下， 以 水 、 1,4-二氧六环 为溶剂， 70.0 ℃ 、17.77 kPa 条件下， 反应 15.0h， 以to give a quantitative yield (7.24 g) of the title compound的产率得到1-(2-羟基苯基)-哌嗪-4-羧酸叔丁酯
  参考文献：
  名称：

  Certain aryl-aliphatic and heteroaryl-aliphatic piperazinyl pyrazines and their use in the treatment of serotonin-related diseases

  摘要：

  通式（I）的化合物：其中变量如规范中所定义，对于预防或治疗人类或动物中与血清素相关的疾病，尤其是5-HT2受体相关的疾病，特别是与5-HT2c受体相关的疾病，例如进食障碍、记忆障碍、精神分裂症、情绪障碍、焦虑症、疼痛、性功能障碍和泌尿系统疾病非常有用。

  公开号：

  US06465467B1
• 作为产物：
  描述：

  1-(2-甲氧苯基)哌嗪 以49%的产率得到
  参考文献：
  名称：

  MARTIN, GREGORY E.;ELGIN, ROBERT J. (JR);MATHIASEN, JOANNE R.;DAVIS, CORA+, J. MED. CHEM., 32,(1989) N, C. 1052-1056

  摘要：

  DOI：

文献信息

• Method of treating anxiety with 5-[(4-aryl or
  申请人：A. H. Robbins Company, Incorporated

  公开号：US05162322A1

  公开（公告）日：1992-11-10

  This invention discloses the antianxiety properties of compounds of the formula: ##STR1## wherein n is 3 or 4, R is C.sub.1 -C.sub.4 alkyl or phenyl, and Ar is ##STR2## where Z is selected from H, C.sub.1 -C.sub.4 alkoxy, C.sub.2 -C.sub.4 alkenyloxy or hydroxy.

  本发明披露了以下化合物的抗焦虑特性：##STR1## 其中n为3或4，R为C.sub.1-C.sub.4烷基或苯基，Ar为##STR2## 其中Z选自H，C.sub.1-C.sub.4烷氧基，C.sub.2-C.sub.4烯氧基或羟基。
• Benzopyranones, a method for producing them and uses therefor
  申请人：Dr. Willmar Schwabe GmbH & Co.

  公开号：US05428038A1

  公开（公告）日：1995-06-27

  Novel 2H-1-benzopyran-2-ones (coumarin derivatives) of the general formula (I) are provided: ##STR1## wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, X and Y are defined as in the specification, and the addition compounds thereof with physiologically compatible acids, intermediates and methods for the preparation thereof. The coumarin compounds possess a neuroprotective and anti-allergic action.

  提供一般式(I)的小说2H-1-苯并吡喃-2-酮（香豆素衍生物）：##STR1## 其中R.sup.1，R.sup.2，R.sup.3，R.sup.4，X和Y如规范中定义，并且与生理兼容酸的加合物，中间体及其制备方法。香豆素化合物具有神经保护和抗过敏作用。
• CERTAIN ARYLALIPHATIC AND HETEROARYL-ALIPHATIC PIPERAZINYL PYRAZINES AND THEIR USE IN THE TREATMENT OF SEROTONIN-RELATED DISEASES
  申请人：Biovitrum, AB, a Stockholm, Sweden corporation

  公开号：US20040242554A1

  公开（公告）日：2004-12-02

  The invention relates to compounds of the general formula (I): 1 wherein Ar is optionally substituted aryl or heteroaryl; A is (i) —O—, —S—, —SO 2 —, —NH—, (ii) a C 1-4 -alkyl- or C 1-6 -acyl-substituted nitrogen atom or (iii) a C 1-8 -alkylene chain or a heteroalkylene chain having 2 to 8 chain atoms, which optionally contains at least one unsaturation, and which may be substituted and/or contain a bridge to form a saturated or partially or fully unsaturated ring having 3-8 ring members; B is —C(R 4 )(R 5 )—, —OC(R 4 )(R 5 )—, —N(R 6 )C(R 4 )(R 5 )—, —N(R 6 )—, —O—, —S— or —SO 2 —; R is optionally substituted C 3-8 -cycloalkyl, aryl or heteroaryl; R 1 is (i) a saturated or unsaturated azacyclic or aminoazacyclic ring, or a saturated diazacyclic or aminodiazacyclic ring, which has 4 to 7 ring members, or a saturated aminoazabicyclic, azabicyclic or diazabicyclic ring which has 7 to 10 ring members, which rings optionally are substituted in one or more positions, or a group —[C(R 4 )(R 5 )] x N(R 2a )(R 3a )]; R 2a , R 3a , R 4 , R 5 , R 6 and x are as defined in the claims, and n is 0 or 1; and pharmaceutically acceptable salts, hydrates and prodrug forms thereof. The compounds may be prepared by per se conventional methods and can be used for treating a human or animal subject suffering from a serotonin-related disorder, such as eating disorders, especially obesity, memory, disorders, schizophrenia, mood disorders, anxiety disorders, pain, sexual dysfunctions, and urinary disorders. The invention also relates to such use as well as to pharmaceutical compositions comprising a compound of formula (I).

  本发明涉及通式（I）的化合物：其中Ar是可选取代的芳基或杂芳基；A是（i）—O—，—S—，—SO2—，—NH—，（ii）C1-4烷基或C1-6酰基取代的氮原子，或（iii）C1-8烷基链或具有2-8链原子的杂烷基链，其可选包含至少一个不饱和度，并且可以取代和/或含有桥接以形成具有3-8环成员的饱和或部分或完全不饱和环；B是—C（R4）（R5）—，—OC（R4）（R5）—，—N（R6）C（R4）（R5）—，—N（R6）—，—O—，—S—或—SO2—；R是可选取代的C3-8环烷基，芳基或杂芳基；R1是（i）饱和或不饱和的氮杂环或氨基氮杂环，或饱和的二氮杂环或氨基二氮杂环，其具有4-7环成员，或饱和的氨基氮杂双环、氮杂双环或二氮杂双环，其具有7-10环成员，这些环在一个或多个位置上可选取代，或者是一个组—[C（R4）（R5）]xN（R2a）（R3a）；R2a，R3a，R4，R5，R6和x如权利要求中所定义，n为0或1；以及其药学上可接受的盐、水合物和前药形式。这些化合物可以通过常规方法制备，并可用于治疗患有血清素相关疾病的人或动物，例如进食障碍，尤其是肥胖症，记忆障碍，精神分裂症，情绪障碍，焦虑障碍，疼痛，性功能障碍和泌尿系统疾病。本发明还涉及这种用途以及包含通式（I）化合物的制药组合物。
• Derivatives of (AZA)naphthalenesultam, their preparation and
  申请人：Rhone-Poulenc Sante

  公开号：US05021420A1

  公开（公告）日：1991-06-04

  This invention relates to a compound ##STR1## in which R.sub.1 represents a 1,2,3,6-tetrahydro-1-pyridyl radical substituted in the 4-position by (a) a phenyl radical, (b) a phenyl radical substituted by a halogen atom or an alkyl, hydroxy or alkoxy radical, (c) a 3-indolyl radical, (d) a 3-indolyl radical substituted on the nitrogen atom by an alkyl or alkylcarbonyl radical and/or in the 5-position by a halogen atom or (e) a 3-(5-hydroxyindolyl) radical. a 1-piperazinyl radical substituted in the 4-position by (a) a phenyl radical, (b) a phenyl radical substituted by an alkoxy, alkyl, hydroxy, nitro or amino radical or a halogen atom, (c) a 1,2-benzisothiazol-3-yl radical, (d) a 1,2-benzisoxazol-3-yl radical or (e) a 2-pyridyl radical. a piperidino radical substituted in the 4-position by (a) a phenyl radical, (b) a phenyl radical substituted by a halogen atom or a hydroxy, alkyl or alkoxy radical, (c) two phenyl radicals, (d) a bis(4-fluorophenyl)methylene radical, (e) a 4-fluorobenzoyl radical, (f) a 2-oxo-1-benzimidazolinyl radical, (g) a 2-oxo-1-benzimidazolinyl radical substituted in the 3-position by an alkylcarbonyl or benzoyl radical, (b) a hydroxy radical and a phenyl radical optionally substituted with an alkyl, alkoxy or hydroxy radical or a halogen atom, (i) a 3-indolyl radical, (j) a 3-indolyl radical substituted on the nitrogen atom by an alkyl or alkylcarbonyl radical and/or in the 5-position by a halogen atom or (k) a 3-(5-hydroxyindolyl) radical. either: R.sub.2 and R.sub.3, which are identical, represent a hydrogen or halogen atom and R.sub.4 represents a hydrogen atom or R.sub.2 and R.sub.4 represent a hydrogen atom and R.sub.3 represents a halogen atom or an acetylamino radical or R.sub.2 and R.sub.3 represent a hydrogen atom and R.sub.4 represents a halogen atom and R.sub.5 represents a --CH.dbd. group. or R.sub.2, R.sub.3 and R.sub.4 represent a hydrogen atom and R.sub.5 represents a nitrogen atom. R.sub.6 represents an alkylene chain containing 2 to 4 carbon atoms or a propylene chain substituted in the 1- or 3-position by an alkyl radical or in the 2-position by an alkyl, alkoxy, hydroxy, dialkylamino, piperidino, morpholino or thiomorpholino radical, with the reservation that when R.sub.6 represents a propylene radical substituted in the 2-position by a dialkylamino, piperidino, morpholino or thiomorpholino radical, R.sub.1 cannot be a radical containing a hydroxy radical, and their salts, are useful in therapy for their ability to block serotonin receptors.

  本发明涉及化合物##STR1## 其中R.sub.1代表1,2,3,6-四氢-1-吡啶基取代在4位上的基团，所述基团可以是(a)苯基基团，(b)被卤素原子或烷基、羟基或烷氧基取代的苯基基团，(c)3-吲哚基基团，(d)在氮原子上取代烷基或烷基羰基基团和/或在5位上取代卤素原子的3-吲哚基基团，或(e)3-(5-羟基吲哚基)基团；1-哌嗪基取代在4位上的基团，所述基团可以是(a)苯基基团，(b)被烷氧基、烷基、羟基、硝基或氨基基团或卤素原子取代的苯基基团，(c)1,2-苯并异噻唑-3-基基团，(d)1,2-苯并异恶唑-3-基基团或(e)2-吡啶基基团；取代在4位的哌啶基基团，所述基团可以是(a)苯基基团，(b)被卤素原子或羟基、烷基或烷氧基取代的苯基基团，(c)两个苯基基团，(d)双(4-氟苯基)亚甲基基团，(e)4-氟苯甲酰基基团，(f)2-氧代-1-苯并咪唑啉基团，(g)在3位上取代烷基羰基或苯甲酰基基团的2-氧代-1-苯并咪唑啉基团，(h)羟基基团和一个苯基基团，所述苯基基团可以选择取代烷基、烷氧基或羟基基团或卤素原子，(i)3-吲哚基基团，(j)在氮原子上取代烷基或烷基羰基基团和/或在5位上取代卤素原子的3-吲哚基基团，或(k)3-(5-羟基吲哚基)基团。R.sub.2和R.sub.3相同，分别代表氢原子或卤素原子，R.sub.4代表氢原子，或者R.sub.2和R.sub.4代表氢原子，R.sub.3代表卤素原子或乙酰氨基基团，或者R.sub.2和R.sub.3代表氢原子，R.sub.4代表卤素原子，R.sub.5代表--CH.dbd.基团，或者R.sub.2、R.sub.3和R.sub.4代表氢原子，R.sub.5代表氮原子。R.sub.6代表含有2到4个碳原子的烷基链或在1位或3位上取代烷基基团或在2位上取代烷基、烷氧基、羟基、二烷基氨基、哌啶基、吗啉基或硫代吗啉基的丙烯基链，但当R.sub.6代表在2位上取代二烷基氨基、哌啶基、吗啉基或硫代吗啉基的丙烯基链时，R.sub.1不能是含有羟基基团的基团。这些化合物及其盐在治疗中具有阻断血清素受体的能力。
• Derivatives of (AZA) naphthalensultam, their preparation and
  申请人：Rhone-Poulenc Sante

  公开号：US05036075A1

  公开（公告）日：1991-07-30

  This invention relates to a compound of the formula: ##STR1## in which R.sub.1 represents a 1,2,3,6-tetrahydro-1-pyridyl radical substituted in the 4-position. a 1-piperazinyl radical substituted in the 4-position. a piperidino radical substituted in the 4-position either: R.sub.2 and R.sub.3, which are identical, represent a hydrogen or halogen atom and R.sub.4 represents a hydrogen atom or R.sub.2 and R.sub.4 represent a hydrogen atom and R.sub.3 represents a halogen atom or an acetylamino radical or R.sub.2 and R.sub.3 represent a hydrogen atom and R.sub.4 represents a halogen atom and R.sub.5 represents a --CH.dbd. group. or R.sub.2, R.sub.3 and R.sub.4 represent a hydrogen atom and R.sub.5 represents a nitrogen atom. R.sub.6 represents an alkylene chain containing 2 to 4 carbon atoms or a propylene chain substituted in the 1- or 3-position by an alkyl radical or in the 2-position by an alkyl, alkoxy, hydroxy, dialkylamino, piperidino, morpholino or thiomorpholino radical, and their salts, are useful in therapy for their ability to block serotonin receptors.

  本发明涉及一种式为：##STR1##其中R.sub.1代表在4位取代的1,2,3,6-四氢-1-吡啶基基团，4位取代的1-哌嗪基基团或4位取代的哌啶基基团，其中：R.sub.2和R.sub.3相同，代表氢或卤素原子，R.sub.4代表氢原子，或R.sub.2和R.sub.4代表氢原子，R.sub.3代表卤素原子或乙酰氨基基团，或R.sub.2和R.sub.3代表氢原子，R.sub.4代表卤素原子，R.sub.5代表--CH.dbd.基团，或R.sub.2、R.sub.3和R.sub.4代表氢原子，R.sub.5代表氮原子。R.sub.6代表含有2至4个碳原子的烷基链或在1-或3-位被烷基基团取代的丙烯基链，或在2-位被烷基、烷氧基、羟基、二烷基氨基基团、哌啶基、吗啉基或硫代吗啉基取代的丙烯基链，以及它们的盐，用于治疗因其阻断5-羟色胺受体的能力而具有的功效。